Melanoma: Lange JR

Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK, Anonymous00048. · No affiliation provided · J Natl Compr Canc Netw. · Pubmed #19401060 No free full text.

This publication has no abstract.

Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ, Anonymous00370. · No affiliation provided · J Natl Compr Canc Netw. · Pubmed #16884669 No free full text.

This publication has no abstract.

Jacobs LK, Lange JR, Balch CM. · No affiliation provided · Ann Surg Oncol. · Pubmed #18320286 links to  free full text

This publication has no abstract.

Lange JR, Balch CM. · Johns Hopkins Medicine, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD 21287, USA. · Surg Oncol Clin N Am. · Pubmed #16226692 No free full text.

Abstract: Current data do not support widespread population-based screening for melanoma. While the incidence of melanoma is high, the overall mortality is low, and thus any potential benefit of screening the general population is hard to demonstrate. No randomized controlled trial showing reduction in mortality has ever been completed and, given the expense and time necessary for such a trial, probably will never be completed. The idea of skin screening remains appealing for this common, visible malignancy which is eminently treatable when detected early. Efforts should be focused on populations at particularly high risk of developing melanoma and on those at high risk of death from melanoma once diagnosed. Persons in kindreds of familial melanoma, and persons who have atypical mole syndrome, those who have a prior diagnosis of melanoma, or those who have diagnosed atypical nevi are all reasonable candidates for routine screening, based on lower-level evidence in the absence of randomized clinical trials targeting these groups. Programs targeting persons of low socioeconomic status and targeting white men over the age of 50 could address groups known to beat especially high risk of melanoma mortality.

Lange JR. · Division of Surgical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.. · Dermatol Surg. · Pubmed #10940072 No free full text.

This publication has no abstract.

Baisden BL, Askin FB, Lange JR, Westra WH. · Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. · Am J Surg Pathol. · Pubmed #10935655 No free full text.

Abstract: Despite the profound therapeutic and prognostic implications of nodal metastases in patients with melanoma, there is no consensus strategy for the optimal detection of metastases in sentinel lymph node biopsies. Traditional microscopic examination may be too crude to detect scattered, individual tumor cells. Conversely, molecular genetic techniques are prone to false-positive results. The authors evaluated the ability of HMB-45 immunohistochemistry to enhance detection of melanoma cells in histologically negative sentinel lymph nodes. Ninety-six sentinel lymph nodes, collected over a 25-month period from 66 consecutive patients with melanoma, were processed routinely and sectioned serially. Slides 1, 3, and 5 were stained with hematoxylin and eosin. HMB-45 staining was performed on an intervening slide in histologically negative nodes. To assess the background incidence of HMB-45-positive cells in lymph nodes draining the skin, the authors stained 244 cervical and axillary lymph nodes from patients without melanoma. Metastases were apparent microscopically in 12 (18%) of the 66 patients with melanoma. Of the remaining 54 patients, four patients (7%) had lymph nodes harboring individual, scattered HMB-45-positive cells. Benign nevocellular aggregates were present in four of the 96 sentinel lymph nodes (4% nodal incidence), but they were HMB-45-negative. The authors did not observe a single HMB-45-positive cell in the 244 lymph nodes from patients without melanoma. Immunohistochemistry appears to represent a specific means of enhancing tumor detection in sentinel lymph nodes from patients with melanoma.

Bilimoria KY, Balch CM, Wayne JD, Chang DC, Palis BE, Dy SM, Lange JR. · Cancer Programs, American College of Surgeons, Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. · J Clin Oncol. · Pubmed #19273706 No free full text.

Abstract: PURPOSE: Guidelines recommend sentinel lymph node biopsy (SLNB) for patients with clinical stage IB/II melanomas, but not clinical stage IA melanoma. This study examines factors associated with SLNB use for clinically node-negative melanoma. METHODS: Patients diagnosed with clinically node-negative invasive melanoma in 2004 and 2005 were identified from the National Cancer Data Base. Regression models were developed to assess the association of clinicopathologic (sex, age, race/ethnicity, comorbidities, T stage), socioeconomic (insurance status, educational level, income), and hospital (hospital type, geographic area) factors with SLNB use. RESULTS: A total of 16,598 patients were identified: 8,073 patients with clinical stage IA and 8,525 patients with clinical stage IB/II melanoma. For clinical stage IB/II melanoma, SLNB use was reported in 48.7% of patients. Patients with clinical stage IB/II melanoma were less likely to undergo SLNB if they were older than 75 years; had T1b tumors, no tumor ulceration, or head/neck or truncal lesions; were covered by Medicaid or Medicare; or lived in the Northeast, South, or West census regions. SLNB use was reported in 13.3% of patients with clinical stage IA melanoma and was more likely in patients who were younger than 56 years or lived in the Mountain or Pacific census regions. Patients treated at National Comprehensive Cancer Network-or National Cancer Institute-designated hospitals were most likely to undergo SLNB in adherence with national consensus guidelines. CONCLUSION: SLNB use was associated with clinicopathologic factors but also with health system factors, including type of insurance, geographic area, and hospital type. These findings have implications for provider education and health policy.

Hueman MT, Lange JR. · Johns Hopkins Medicine, Baltimore, MD 21287, USA. · Curr Treat Options Oncol. · Pubmed #18998214 No free full text.

Abstract: Sentinel lymph node biopsy (SLNB) for patients with newly diagnosed localized invasive melanoma provides excellent prognostic information and results in improved regional disease control. Prior to the common use of SLNB, regional nodal recurrence was the single most common site of melanoma recurrence, with symptomatic, bulky disease that could be disabling and difficult or impossible to control. With the widespread use of SLNB, regional recurrence of melanoma is much less frequent. Even without clear evidence of improvement in overall survival, the significant and reliable prognostic information and the improved regional control make sentinel node biopsy an important procedure that should be offered routinely to many patients with newly diagnosed melanoma.

Bilimoria KY, Balch CM, Bentrem DJ, Talamonti MS, Ko CY, Lange JR, Winchester DP, Wayne JD. · Cancer Programs, American College Surgeons, Chicago, IL, USA. · Ann Surg Oncol. · Pubmed #18414952 No free full text.

Abstract: BACKGROUND: Currently, complete lymph node dissection (CLND) is recommended after identification of a metastatic lymph node by sentinel lymph node biopsy (SLNB). Guidelines suggest that CLND should be performed as a separate procedure, and a sufficient number of nodes should be examined. Our objective was to examine the utilization, timing, and adequacy of CLND for melanoma in the United States. METHODS: From the National Cancer Data Base, patients diagnosed with stage I to III melanoma during 2004-2005 were identified. Multiple logistic regression was used to assess factors associated with CLND utilization, timing (separate operation from SLNB), and adequacy (examination of > or = 10 nodes). RESULTS: Of the 44,548 patients identified, 47.5% were pathologic stage IA, 23.8% stage IB, 14.1% stage II, and 14.6% stage III. Of the 17% (2942 of 17,524) with nodal metastases on SLNB, only 50% underwent a CLND. Patients were significantly less likely to undergo a CLND after SLNB if > 75 years old or had lower extremity melanomas. Of the patients who underwent a CLND, only 42% underwent the CLND at a separate procedure after the SLNB. Of those who underwent a CLND, 69.2% had > or = 10 nodes examined. Patients were significantly less likely to have > or = 10 nodes examined if they were > 75 years old or had lower extremity melanomas. Patients treated at NCCN/NCI-designated centers were significantly more likely to undergo nodal evaluation in concordance with established guidelines. CONCLUSIONS: Only half of patients with sentinel node-positive melanoma underwent CLND. Quality surveillance measures are needed to monitor, standardize, and improve the care of patients with malignant melanoma.

Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. · Department of Surgery, Johns Hopkins Medicine, Baltimore, MD, USA · J Clin Oncol. · Pubmed #17416855 No free full text.

Abstract: PURPOSE: This study examines the demographics, presentation, and outcomes of children and teenagers with melanoma using a US hospital-based oncology database. PATIENTS AND METHODS: Data from the National Cancer Data Base from 1985 through 2003 were examined for demographics, presentation, and survival of patients aged 1 to 19 years, as well as a comparison group of patients aged 20 to 24 years. Two-sided linear and Pearson chi2 tests were calculated to examine associations. Proportions were compared using two-sided z tests. Five-year overall observed survival was evaluated using the Kaplan-Meier method and the log-rank test. Cox proportional hazards regression was used to estimate risk of mortality. RESULTS: Of 3,158 patients aged 1 to 19 years, 96.3% had cutaneous melanoma, 3.0% had ocular melanoma, and 0.7% had an unknown primary tumor. Cutaneous melanoma in patients aged 1 to 19 years was more common in girls (55.5%) and patients older than 10 years (90.5%). The demographics and presentation of cutaneous melanoma were age related; younger children were significantly more likely to be nonwhite and male and more likely to present with a head and neck primary tumors and with regional or distant metastases (linear chi2, P < .001 for sex, race, and extent of disease). Poorer survival was associated with higher stage and younger age. In contrast to patients aged 20 to 24 years, survival was not related to thickness in patients aged 1 to 19 years with localized invasive melanoma. CONCLUSION: Melanoma in children and teenagers differs from melanoma in young adults in demographics, presentation, and survival. Further investigation is warranted to elucidate possible biologic correlates of the unique aspects of melanoma in children and teenagers.

Lange JR, Balch CM. · Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA. · Pediatrics. · Pubmed #15741391 links to  free full text

This publication has no abstract.

Koch SE, Lange JR. · Department of Dermatology, Oregon Health Sciences University, Portland 97201-3098, USA. · J Am Acad Dermatol. · Pubmed #10775846 No free full text.

Abstract: BACKGROUND: Cutaneous melanoma is often recognized by its dark color, but some tumors have little or no pigmentation. OBJECTIVE: We present the clinical findings of 4 cases of primary cutaneous amelanotic melanoma in which the clinical diagnosis was unsuspected and one case of amelanotic metastatic melanoma. METHODS: Five cases of melanoma are reviewed. The clinical morphology of the lesions is presented and discussed. We surveyed the literature regarding conditions that mimic amelanotic melanoma, and we discuss the treatment and prognosis for amelanotic melanoma. RESULTS: Amelanotic melanoma may masquerade as a variety of other conditions leading to a delay in the diagnosis or an inappropriate biopsy technique. The prognosis of amelanotic primary tumors is no different from that for its pigmented counterpart. CONCLUSION: The clinician should be familiar with the presentation of amelanotic melanoma to facilitate prompt diagnosis.

Epstein DS, Lange JR, Gruber SB, Mofid M, Koch SE. · Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA. · JAMA. · Pubmed #10029126 links to  free full text

Abstract: CONTEXT: In cutaneous melanoma, tumor depth remains the best biologic predictor of patient survival. Detection of prognostically favorable lesions may be associated with improved survival in patients with melanoma. OBJECTIVE: To determine melanoma detection patterns and relate them to tumor thickness. DESIGN: Interview survey. SETTING AND PATIENTS: All patients with newly detected primary cutaneous melanoma at the Melanoma Center, Johns Hopkins Medical Institutions, between June 1995 and June 1997. MAIN OUTCOME MEASURE: Tumor thickness grouped according to detection source. RESULTS: Of the 102 patients (47 men, 55 women) in the study, the majority of melanomas were self-detected (55%), followed by detection by physician (24%), spouse (12%), and others (10%). Physicians were more likely to detect thinner lesions than were patients who detected their own melanomas (median thickness, 0.23 mm vs 0.9 mm; P<.001). When grouped according to thickness, 11 (46%) of 24 physician-detected melanomas were in situ, vs only 8 (14%) of 56 patient-detected melanomas. Physician detection was associated with an increase in the probability of detecting thinner (< or =0.75 mm) melanomas (relative risk, 4.2; 95% confidence interval, 1.4-11.1; P=.01). CONCLUSIONS: Thinner melanomas are more likely to have been detected by physicians. Increased awareness by all physicians may result in greater detection of early melanomas.